We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+9.09%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$5.62B
AUM Growth
+$874M
Cap. Flow
+$536M
Cap. Flow %
9.53%
Top 10 Hldgs %
66.07%
Holding
710
New
128
Increased
146
Reduced
103
Closed
149

Top Buys

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$779M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$358M
3
NEWR
New Relic, Inc.
NEWR
+$258M
4
DEN
Denbury Inc.
DEN
+$175M
5
VMW
VMware, Inc
VMW
+$165M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$230M
2
PDCE
PDC Energy, Inc.
PDCE
+$221M
3
UNVR
Univar Solutions Inc.
UNVR
+$219M
4
FOCS
Focus Financial Partners Inc. Class A
FOCS
+$146M
5
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$141M

Sector Composition

Rank Sector Weight
1 Technology 34.82%
2 Healthcare 28.77%
3 Real Estate 5.15%
4 Financials 4.39%
5 Consumer Discretionary 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HPP
301
Hudson Pacific Properties
HPP
$729M
$1.13M 0.02%
+24,171
New +$1.04M
IMUX icon
302
Immunic
IMUX
$198M
$1.12M 0.02%
76,169
-3,000
-4% -$57.7K
CC icon
303
Chemours
CC
$2.27B
$1.11M 0.02%
39,671
-65,400
-62% -$2.25M
ZURA icon
304
Zura Bio
ZURA
$542M
$1.1M 0.02%
167,167
– –
IOVA icon
305
Iovance Biotherapeutics
IOVA
$2.77B
$1.1M 0.02%
241,974
-47,410
-16% -$310K
ADPT icon
306
Adaptive Biotechnologies
ADPT
$3.75B
$1.1M 0.02%
201,340
+1,500
+0.8% +$9.92K
IRON icon
307
Disc Medicine
IRON
$2.97B
$1.09M 0.02%
23,121
+6,000
+35% +$300K
MRVL icon
308
Marvell Technology
MRVL
$189B
$1.08M 0.02%
20,000
+5,000
+33% +$295K
DISH
309
PUT
DELISTED
DISH Network Corp.
DISH
$1.07M 0.02%
126,400
– –
OCUL icon
310
Ocular Therapeutix
OCUL
$1.92B
$1.07M 0.02%
342,111
+40,000
+13% +$164K
COTY icon
311
PUT
Coty
COTY
$2.39B
$1.05M 0.02%
+1,418,000
New +$16.7M
RVNC
312
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.02M 0.02%
+88,800
New +$1.71M
SDGR icon
313
Schrodinger
SDGR
$1.33B
$1.01M 0.02%
35,700
+21,500
+151% +$866K
ACRV icon
314
Acrivon Therapeutics
ACRV
$72.3M
$1M 0.02%
105,000
+5,000
+5% +$57.8K
PRAX icon
315
Praxis Precision Medicines
PRAX
$10.3B
$998K 0.02%
38,903
– –
DYN icon
316
Dyne Therapeutics
DYN
$4.83B
$992K 0.02%
110,752
-65,000
-37% -$700K
TARS icon
317
Tarsus Pharmaceuticals
TARS
$2.87B
$982K 0.02%
55,262
-48,000
-46% -$849K
SLN
318
Silence Therapeutics
SLN
$554M
$967K 0.02%
98,326
– –
ACAH
319
DELISTED
Atlantic Coastal Acquisition Corp. Class A Common Stock
ACAH
$965K 0.02%
90,632
– –
FCPT icon
320
Four Corners Property Trust
FCPT
$2.75B
$960K 0.02%
+43,260
New +$1.09M
PTCT icon
321
PTC Therapeutics
PTCT
$5.91B
$955K 0.02%
42,601
-2,500
-6% -$93K
CGEM icon
322
Cullinan Oncology
CGEM
$1.16B
$950K 0.02%
105,000
+20,000
+24% +$208K
HYG icon
323
PUT
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$16.6B
$935K 0.02%
+1,400,000
New +$105M
CRC icon
324
California Resources
CRC
$4.67B
$932K 0.02%
16,648
-356
-2% -$19K
ATXS
325
DELISTED
Astria Therapeutics
ATXS
$925K 0.02%
124,000
+10,000
+9% +$85.3K
11 12
13
14 15

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
SAG
SageView Advisory Group Newport Beach, California $2.96B AUM 15.81% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.4B AUM 18.8% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return

UBS O'Connor's Q3 2023 Portfolio in Review

As of Q3 2023, UBS O'Connor held 710 positions worth $5.62B, up 18% from $4.75B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

UBS O'Connor deployed $536M of net new capital in Q3 2023, opening 128 new positions and adding to 146 existing holdings. Its largest new stake was Denbury Inc.: 1,931,731 shares worth $189M.

By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 16% a quarter earlier, followed by Healthcare and Real Estate.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $19.7M trimmed.

  • UBS O'Connor's largest Q3 2023 buy was Denbury Inc.: 1,931,731 shares worth $189M.
  • UBS O'Connor added most to Activision Blizzard in Q3 2023, an estimated $779M increase.
  • UBS O'Connor's biggest Q3 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $19.7M.
  • UBS O'Connor fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $230M.
  • UBS O'Connor's ten largest holdings make up 66% of its $5.62B portfolio in Q3 2023.
  • UBS O'Connor opened 128 new positions and closed 149 in Q3 2023.
  • UBS O'Connor's portfolio value rose 18% quarter-over-quarter to $5.62B.

Based on UBS O'Connor's 13F filing for Q3 2023, filed 14 Nov 2023.